Page 20 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $3.14
52wk Low $0.36 Cadrenal Therapeutics, Inc. CVKD $0.41
822 A1A North
Ponte Vedra, FL 32082

(USD - in millions) www.cadrenal.com
Market Cap 6.6
Enterprise (1.8)
Basic Shares Out. 16.01 COMPANY OVERVIEW
Float 8.02
Institutional Holdings 3.40% Detailed Analysis:Channelchek.com
Short Interest 0.04
Avg. 90-Day Volume 0.47 Cadrenal Therapeutics is developing tecarfarin for unmet needs in
anticoagulation therapy. Tecarfarin is a late-stage novel oral and
reversible anticoagulant (blood thinner) to prevent heart attacks,
strokes, and deaths due to blood clots in patients with rare
EPS Data cardiovascular conditions. Tecarfarin has orphan drug and fast-track
designations from the FDA for the prevention of systemic
2021 2022 2023 thromboembolism (blood clots) of cardiac origin in patients with end-
CQ1 N/A N/A N/A stage kidney disease (ESKD) and atrial fibrillation (AFib) and just
CQ2 N/A N/A N/A received orphan drug designation for the prevention of thrombosis and
thromboembolism in patients with ventricular assist devices (VADs).
CQ3 N/A N/A N/A
CQ4 N/A N/A (0.13)
CY N/A N/A (0.55) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.59
ROE (ttm) -780.59
Debt-to-Total Cap. (mrq) 0.28
Fiscal Year End 31-Dec
822 A1A NorthPonte Vedra FL 32082

Key Executives
CEO: Pham, Quang
CFO: Szot, Matthew
COO: Cole, Jeffrey
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures